AIDS

Pandemic Accord Must Work for All, says AHF

Retrieved on: 
Monday, April 8, 2024
Advocacy Group Opinion, Infectious Diseases, COVID-19, Health, Public Policy, Government, World Health Day, AHF, Public, AIDS, World Health Assembly, AIDS Healthcare Foundation

“The COVID-19 pandemic exposed how woefully unprepared we were in responding to deadly outbreaks – and sadly, four years later, we are still not prepared for the next big health crisis,” said AHF President Michael Weinstein.

Key Points: 
  • “The COVID-19 pandemic exposed how woefully unprepared we were in responding to deadly outbreaks – and sadly, four years later, we are still not prepared for the next big health crisis,” said AHF President Michael Weinstein.
  • “World leaders must get the Pandemic Accord back on track and negotiate it in good faith for the entire world—not just what’s best for their political and financial interests.
  • The new pandemic agreement must be based on transparency, accountability, and cooperation.
  • If World Health Assembly Member States fail to heed lessons from the past pandemic, the world will be right back where we started with COVID-19.

ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

Retrieved on: 
Monday, April 8, 2024
Research, Infectious Diseases, FDA, LGBTQ+, AIDS, Pharmaceutical, Consumer, Health, Science, Other Science, ARV, Week, DANCE, ViiV Healthcare, Pfizer, TANGO, HIV, GSK, Ageing, Safety, Subtypes of HIV, Shionogi, Food, Pharmaceutical industry

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.1

Key Points: 
  • ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.1
    In the U.S., 20 percent of new HIV diagnoses in 2020 were among young people aged 13-24.2 This expanded indication marks the first time an oral, two-drug, single-tablet regimen is available for adolescents between 12- and 18-years old living with HIV and underscores ViiV Healthcare’s ongoing commitment to bringing more therapeutic options to young people.
  • Lynn Baxter, Head of North America at ViiV Healthcare, said: "This expanded indication for Dovato brings an oral, two-drug, single-tablet regimen to adolescents living with HIV, providing a complete HIV therapy with fewer ARV medicines – an important consideration for young people who will require lifelong treatment.
  • As a leader in HIV, ViiV Healthcare is proud of our focused efforts to improve and expand care for children and adolescents and we remain committed to addressing the existing treatment gaps in these communities.”
    The approval is supported by data from the DANCE study which evaluated Dovato in treatment-naïve adolescents as well as evidence from well-controlled trials in adults living with HIV, GEMINI-1 and GEMINI-2 (treatment-naïve adults) and TANGO (treatment-experienced adults).1 Results from the DANCE study, which included adolescents between 12- and 18-years old weighing at least 25 kg with HIV-1 RNA 1000 to ≤500,000 c/mL, showed that 26/30 participants achieved and maintained viral suppression at Week 48.1 The safety and efficacy data in adolescents from the DANCE study were comparable to those observed in adults.1 Exposures for components of Dovato were higher but were not clinically significant.1

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

PhRMA Secretly Funds Campaign to Kill Rent Control, per Justice for Renters

Retrieved on: 
Thursday, April 4, 2024
AIDS, Health, Consumer, Public Policy, Government, Residential Building & Real Estate, Pharmaceutical, Advocacy Group Opinion, Professional Services, Construction & Property, Environmental, Social and Governance (ESG), General Health, Seniors, State, Local, Other Policy Issues, Issue, AIDS Healthcare Foundation, Risk, Patient, Greater Los Angeles, Housing, Justice, Big Pharma, AHF, Pharmacy, Advertising, Property management

This latest move is part of an ongoing shell game carried out by PhRMA and the pharmaceutical companies it represents to avoid public scrutiny, including that of the press.

Key Points: 
  • This latest move is part of an ongoing shell game carried out by PhRMA and the pharmaceutical companies it represents to avoid public scrutiny, including that of the press.
  • “This is a shining example of how corporate greed puts both patients and tenants at risk,” said Susie Shannon, campaign manager for Justice for Renters .
  • PhRMA has a PAC called the Pharmaceutical Research and Manufacturers of America California Initiative Fund.
  • That PAC contributed an initial $10,000 to the California Business Roundtable PAC, which in turn contributed $250,000 to Californians to Protect Affordable Housing, a PAC opposing the Justice for Renters Act.

Pharmaceutical Industry Medical Affairs and Market Access Veteran John Byrd, PhD, MBA to Join AESARA as VP, Management Consulting

Retrieved on: 
Wednesday, April 3, 2024
Health Technology, Health Insurance, Other Health, Marketing, Pharmaceutical, Practice Management, Communications, Managed Care, Mental Health, General Health, Hospitals, Biotechnology, Alternative Medicine, AIDS, Health, GSK, Boehringer Ingelheim, Market access, Novartis, Management consulting, Communication

We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.

Key Points: 
  • We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.
  • Ruslan Horblyuk, Chief Strategic Consulting Officer at AESARA, said, "John brings an unmatched breadth and depth of Medical Affairs and Market Access expertise at a time when we are focused on expanding our Management Consulting portfolio and capabilities at AESARA.
  • In his prior roles, John set the vision and strategic direction to ensure effective communication and implementation of value evidence, population health management and quality improvement programs.
  • I look forward to helping the company expand the capabilities within management consulting while continuing to deliver bold, innovative, and transformative solutions to our clients,” said John Byrd.

BostonGene Announces Acceptance of Eight Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Technology, AIDS, Health, General Health, Oncology, Health Technology, Medical Devices, Artificial Intelligence, Genetics, Clinical Trials, B-cell lymphoma, TLS, HIV, Patient, Lung, RNA, Abstract, AACR, Blood, San Diego Convention Center, DLBCL, Kidney cancer

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.
  • BostonGene will exhibit at booth #847.
  • BostonGene, together with its collaborators, will deliver presentations on various topics, including the feasibility and utility of using comprehensive genomic and transcriptomic analysis for patients with blood and solid cancers, RNA-based models for TLS prediction in both lung and pancreatic cancers, a transcriptomic-based model to distinguish sarcomatoid features in kidney cancer and the use of comprehensive molecular profiling to evaluate the impact of race and HIV status on the genetic landscape of patients with diffuse large B-cell lymphoma (DLBCL) in southern Africa.
  • Details of BostonGene’s poster presentations at the AACR Annual Meeting are below:

Drug Prices Decline Thanks to President Biden, Notes AHF

Retrieved on: 
Saturday, March 30, 2024
Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, Philanthropy, White House, Federal Government, AIDS, Pharmaceutical, Health, Foundation, Other Policy Issues, IRA, AIDS Healthcare Foundation, Federation, Plasma protein binding, AHF, Medicare, Inflation, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) applauds the Biden administration’s continued efforts to lower prescription drug prices for all Americans.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds the Biden administration’s continued efforts to lower prescription drug prices for all Americans.
  • Multiple provisions in the law bend the prescription drug cost curve down.
  • The U.S. Department of Health and Human Services announced that over 763,000 Medicare beneficiaries will start seeing lower drug prices beginning April 1.
  • “The Medicare Prescription Drug Inflation Rebate Program, the provision responsible for the much-needed savings, slows the rise of prescription drug price increases and shores up the Medicare trust fund.

Coachella Concerned That People Have Sex, Says AHF

Retrieved on: 
Thursday, March 28, 2024
Entertainment, AIDS, Health, Infectious Diseases, Music, Events, Concerts, AIDS Healthcare Foundation, STD, Condom, Syphilis, URL, Sand, Coachella (festival), United, STI, Gonorrhea, CDC, Chlamydia, AHF, Multimedia, Advertising, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Coachella-themed billboard went up Tuesday, March 26, 2024 and will remain up throughout April as Coachella spans two weekends: April 12-14 and April 19-21.
  • Do they really not know how people spend their time during festival weekends?” said Michael Weinstein, AHF president and cofounder.
  • California ranks 22 in reported cases of chlamydia, 18th in reported cases of gonorrhea, and 19th in cases of syphilis.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

AHF’s Just Use It Ad Campaign Named OBIE Award Finalist

Retrieved on: 
Tuesday, March 26, 2024
Public Policy, Government, AIDS, Health, Other Policy Issues, Marketing, Advertising, Communications, Social Activism, AIDS Healthcare Foundation, Just, Partnership, Patient, Public, URL, City, Nonprofit organization, Gold, Burn, AHF, Multimedia, Public service

View the full release here: https://www.businesswire.com/news/home/20240326133990/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240326133990/en/
    AIDS Healthcare Foundation’s (AHF) Just Use It ad campaign – featuring a condom-clad banana, the slogan “Just Use It,” and the useacondom.com URL – is a finalist for the 2024 OBIE Awards, which have been rewarding the best in out-of-home advertising for more than 80 years.
  • This campaign is running in more than a dozen cities across the country; the billboard pictured is in New York City.
  • The Just Use It campaign debuted in August 2023 to promote condom use and ran in six central Los Angeles locations.
  • campaign won a Gold OBIE award in 2017, and AHF was an OBIE finalist with its #StandAgainstHate campaign in 2018.

AHF Cheers Washington State Law to Stop PBM Abuse

Retrieved on: 
Tuesday, March 26, 2024
State, Local, Public Policy, Healthcare Reform, Pharmaceutical, Social Activism, Practice Management, Communications, Managed Care, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Foundation, AIDS, Health, AIDS Healthcare Foundation, Patient, Pharmacy, AHF

Today, Washington Governor Jay Inslee signed SB 5213 into law.

Key Points: 
  • Today, Washington Governor Jay Inslee signed SB 5213 into law.
  • The law protects patients and the pharmacies who serve them from pharmacy benefit managers (PBMs).
  • “We thank Senator Kuderer, Senator Short and the Washington State Pharmacy Association for championing this bill.
  • This bill provides protections for patient care, patient choice and pharmacies,” said Laura Boudreau, Chief of Operations at AIDS Healthcare Foundation (AHF), which worked with the legislators and the Washington State Pharmacy Association to ensure passage of the bill.